Details for Patent: RE48731
✉ Email this page to a colleague
Which drugs does patent RE48731 protect, and when does it expire?
Patent RE48731 protects QINLOCK and is included in one NDA.
Summary for Patent: RE48731
Title: | Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases |
Abstract: | The invention relates to dihydronaphthyridines and related compounds; compositions comprising an effective amount of a dihydronaphthyridine or a related compound; and methods for treating or preventing proliferative diseases comprising the administration of an effective amount of a dihydronaphthyridine or a related compound. |
Inventor(s): | Flynn; Daniel L. (Lawrence, KS), Kaufman; Michael D. (Lawrence, KS), Petillo; Peter A. (Lawrence, KS) |
Assignee: | Deciphera Pharmaceuticals, LLC (Waltham, MA) |
Application Number: | 16/387,315 |
Patent Claim Types: see list of patent claims | Use; | More… ↓ |
Drugs Protected by US Patent RE48731
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Deciphera Pharms | QINLOCK | ripretinib | TABLET;ORAL | 213973-001 | May 15, 2020 | RX | Yes | Yes | RE48731 | ⤷ Subscribe | TREATMENT OF GASTROINTESTINAL STROMAL TUMOR | ⤷ Subscribe | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |